David Moore

Biography

David joins the board of directors with significant biotech and big pharma experience. David is currently the Senior VP Marketing at Novo Nordisk, following his time as the Chief Commercial Officer of Cempra, a clinical-stage pharmaceutical company focused on developing antibacterials to meet critical medical needs. Prior to joining Cempra, David was Chief Business Officer of Ocera Therapeutics, a publicly traded clinical stage biotech focused in advanced liver disease. Prior to Ocera, he was Chief Business Officer of Tranzyme Pharma, a publicly traded clinical stage biotech and macrocyclic discovery chemistry company which David and the management team successfully merged with Ocera Therapeutics in July 2013. David has participated in several rounds of corporate financing, successfully negotiated multiple license deals for both clinical stage products and pre-clinical compounds in addition to the recent strategic merger process. David has an extensive commercial background having spent over 15 years developing and managing pharmaceutical commercial programs with the majority of that time spent with Ortho-McNeil and Janssen divisions of Johnson & Johnson. David received his B.Sc. in Biology from Towson University and an M.B.A. from Lehigh University, and a second graduate degree in Health Policy Excellence from Thomas Jefferson University.

Research Interest

 Liver diseases, Biotechnology